Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
109,272,143
-
Number of holders
-
36
-
Total 13F shares, excl. options
-
1,038,987
-
Shares change
-
-34,450
-
Total reported value, excl. options
-
$3,786,537
-
Value change
-
+$314,929
-
Number of buys
-
21
-
Number of sells
-
-11
-
Price
-
$3.81
Significant Holders of ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) as of Q1 2021
42 filings reported holding ONCY - ONCOLYTICS BIOTECH INC - Common Stock, no par value as of Q1 2021.
ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) has 36 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1,038,987 shares
of 109,272,143 outstanding shares and own 0.95% of the company stock.
Largest 10 shareholders include INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC (277,852 shares), Creative Planning (170,000 shares), TWO SIGMA ADVISERS, LP (92,900 shares), BANK OF AMERICA CORP /DE/ (62,300 shares), CIBC World Markets Inc. (61,992 shares), JPMORGAN CHASE & CO (56,283 shares), MORGAN STANLEY (50,978 shares), CITADEL ADVISORS LLC (49,378 shares), ROYAL BANK OF CANADA (27,381 shares), and GEODE CAPITAL MANAGEMENT, LLC (24,545 shares).
This table shows the top 36 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.